+91 9891296838/9811747774

KADCYLA (ado-trastuzumab emtansine) for injection for intravenous use.
Initial U.S. Approval. Available In India.

KADCYLA (ado-trastuzumab emtansine) for injection is a prescription medicine. KADCYLA (ado-trastuzumab emtansine) for injection is used to treat Ovarian cancer and breast cancer. Brand KADCYLA (ado-trastuzumab emtansine) for injection Can be imported and made available on "Patient Name basis" treatment in India. If you have questions, please email IPN Support Team or Call Indian Pharma Network on +91 9891296838 (Mr. Tarun) / 9811747774 (Mr. Neeraj) for price list or cost in India.

KADCYLA is a prescription medicine. KADCYLA is used to treat HER2-positive breast cancer KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane,separately or in combination. Patients should have either:
• Received prior therapy for metastatic disease, or
• Developed disease recurrence during or within six months of completing adjuvant therapy.

Source content :

KADCYLA (ado-trastuzumab emtansine) for injection injection suppliers for India and other countries. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of KADCYLA (ado-trastuzumab emtansine) for injection injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the KADCYLA (ado-trastuzumab emtansine) for injection injection medicine cost price in India.

The order for KADCYLA (ado-trastuzumab emtansine) for injection injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Trastuzumab emtansine also known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. In the United States, ado-trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy. Approval was based on the EMILIA study,[10] a phase III clinical trial that compared trastuzumab emtansine versus capecitabine (Xeloda) plus lapatinib (Tykerb) in 991 people with unresectable, locally advanced or metastatic HER2-positive breast cancer who had previously been treated with trastuzumab and taxane chemotherapy.[10] This trial showed improved progression-free survival in patients treated with trastuzumab emtansine (median 9.6 vs. 6.4 months), along with improved overall survival (median 30.9 vs. 25.1 months) and safety.

KADCYLA (ado-trastuzumab emtansine) for injection, for intravenous use.
Initial U.S. Approval

Lyophilized powder in single-use vials containing 100 mg per vial or 160 mg per vial.
Please see the Full Prescribing Information, including Patient Information, for KADCYLA.
KADCYLA (ado-trastuzumab emtansine) for injection injection
You must agree before submitting.

News / Update for KADCYLA (ado-trastuzumab emtansine) for injection .

For KADCYLA (ado-trastuzumab emtansine) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

ADC ARX788 Gets Fast Track Status for HER2+ Metastatic Breast Cancer For More Details

Kadcyla approved for post-surgical use in Japan. ReadMore

Steps to access KADCYLA (ado-trastuzumab emtansine) for injection.

Step 1. You send a request for your medicine online:- Submit a request for a specific medicine, or a general request, and your Patient Support Manager will contact you within 24 hours. They will be there to support and guide you in anyway possible to help you get the medicine you need.

Step 2. We verify your prescription and medical details:- Since we help patients access medicines not available in their home country, our first step is to check that the medicine you need is not currently available in your home country. Next we will also verify that you have a prescription from a doctor in your home country for the medicine you need.

Step 3. We source your medicine:- Once we have verified your prescription and medical details, our expert sourcing team will work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.

Step 4. We deliver your medicine:- After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.

Documentation under Named-Patient import

Doctor’s Prescription –
We would require prescription from registered medical practitioner stating product name, dosage, duration of treatment and diagnosis.

Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.

Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process. you can use copy of passport, driving license, employee ID card or any photo id document as your identity card.

KADCYLA (ado-trastuzumab emtansine) for injection exporter and suppliers in India

Can I get anti-cancer medicines even if I am not based in India?
Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find the best price of -
KADCYLA (ado-trastuzumab emtansine) for injection in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
KADCYLA (ado-trastuzumab emtansine) for injection in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
KADCYLA (ado-trastuzumab emtansine) for injection in North America – Mexico.
KADCYLA (ado-trastuzumab emtansine) for injection in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
KADCYLA (ado-trastuzumab emtansine) for injection in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
KADCYLA (ado-trastuzumab emtansine) for injection in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
KADCYLA (ado-trastuzumab emtansine) for injection in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
KADCYLA (ado-trastuzumab emtansine) for injection in Australia and New Zealand.

Room temperature shipping

For this medication, standard shipping applies. This means that a consistent room temperature of 15 to 25°C is maintained during transit.

Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.

Indian Pharma Network (IPN), Delhi India is a leading Pharmaceutical Distributor / Supplier / Exporter / Importer of Anti-Cancer Medicines, used in HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer. Brand Name "KADCYLA (ado-trastuzumab emtansine) for injection" or Generic Name "ado-trastuzumab emtansine for injection" can be imported for personal use under "patient name basis" treatment in Delhi, Noida, Gurgaon, Mumbai, Chennai, Kolkatta, Bangalore, Jaipur, Chandigarh India. Contact us at or call/WhatsApp at +91 9891296838 / 9811747774 to get access as per norms.